Goldman Scarlato & Karon, P.C. Announces Investigation of STEC, Inc.
June 14 2011 - 5:30PM
Business Wire
Goldman Scarlato & Karon, P.C. (“GSK”) commenced an
investigation into the August 5, 2009 secondary offering of shares
by STEC, Inc. (NASDAQ: STEC) (“STEC”) for $31.00 per share. The
investigation is to determine whether STEC violated the federal
securities laws by making false and misleading statements in
documents filed with the U.S. Securities and Exchange Commission in
connection with its August 5, 2009 secondary offering.
What You May Do
If you purchased STEC shares on August 5, 2009 or as part of the
August 5, 2009 Offering and/or have information that would assist
GSK in its investigation or would like to discuss your legal
rights, you may, without obligation or cost to you, e-mail or call
Mark S. Goldman, Esq. at (888) 668-4130 or send an email to
Mr. Goldman at goldman@gsk-law.com.
About Goldman Scarlato & Karon, P.C.
GSK prosecutes securities fraud, consumer fraud, price-fixing,
ERISA class actions, and shareholder-derivative litigation
throughout the United States. The Firm’s lawyers have recovered
hundreds of millions of dollars on behalf of consumers, investors,
and businesses.
To learn more about Goldman Scarlato & Karon, P.C., please
visit our website, www.gsk-law.com.
Simpletech (NASDAQ:STEC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Simpletech (NASDAQ:STEC)
Historical Stock Chart
From Jul 2023 to Jul 2024